146. Intact Sense of Taste and Smell During COVID-19 Infection Is Associated with Absence of of SARS-CoV-2 Spike Protein Antibody Responses within 3 Months of Symptomatic Illness

por Wilson, James M, Gillani, Sheena, Bencshop, Robert, Poorbaugh, Josh, Nirula, Ajay, Zhang, Lin, Keckler, Kody, Weber, Kathleen, Morack, Ralph, Beasley, Stephanie, Brothers, Jennifer, Huhn, Gregory
Publicado 2021

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine

por Huhn, Gregory, Poorbaugh, Josh, Zhang, Lin, Beasley, Stephanie, Nirula, Ajay, Brothers, Jennifer, Welbel, Sharon, Wilson, James, Gillani, Sheena, Weber, Kathleen M., Morack, Ralph, Keckler, Kody, Benschop, Robert J.
Publicado 2022

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoc...

por Sims, Jonathan T., Poorbaugh, Josh, Chang, Ching-Yun, Holzer, Timothy R., Zhang, Lin, Engle, Sarah M., Beasley, Stephanie, Doman, Thompson N., Naughton, Lynn, Higgs, Richard E., Kallewaard, Nicole, Benschop, Robert J.
Publicado 2022

Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression

por Schroderus, Anna-Mari, Poorbaugh, Josh, McElyea, Samantha, Beasley, Stephanie, Zhang, Lin, Näntö-Salonen, Kirsti, Rintamäki, Reeta, Pihlajamäki, Jussi, Knip, Mikael, Veijola, Riitta, Toppari, Jorma, Ilonen, Jorma, Benschop, Robert J., Kinnunen, Tuure
Publicado 2023

Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients

por Sims, Jonathan T., Chang, Ching-Yun, Poorbaugh, Josh, Daniels, Montanea, Beasley, Stephanie L., Zhang, Lin, Rodgers, George H., Lena, Fabio, Lacerenza, Leonardo G., Sposato, Bruno, Dupont, Annabelle, Susen, Sophie, Casalini, Giacomo, Corbellino, Mario, Stebbing, Justin, Krishnan, Venkatesh
Publicado 2022

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

por Benschop, Robert J., Tuttle, Jay L., Zhang, Lin, Poorbaugh, Josh, Kallewaard, Nicole L., Vaillancourt, Peter, Crisp, Melissa, Trinh, Thi Ngoc Vy, Freitas, Joshua J., Beasley, Stephanie, Daniels, Montanea, Haustrup, Natalie, Higgs, Richard E., Nirula, Ajay, Cohen, Myron S., Marovich, Mary
Publicado 2022

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

por Chen, Peter, Datta, Gourab, Grace Li, Ying, Chien, Jenny, Price, Karen, Chigutsa, Emmanuel, Brown‐Augsburger, Patricia, Poorbaugh, Josh, Fill, Jeffrey, Benschop, Robert J., Rouphael, Nadine, Kay, Ariel, Mulligan, Mark J., Saxena, Amit, Fischer, William A., Dougan, Michael, Klekotka, Paul, Nirula, Ajay, Benson, Charles
Publicado 2021

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

por Zhang, Lin, Poorbaugh, Josh, Dougan, Michael, Chen, Peter, Gottlieb, Robert L., Huhn, Gregory, Beasley, Stephanie, Daniels, Montanea, Ngoc Vy Trinh, Thi, Crisp, Melissa, Freitas, Joshua Joaquin, Vaillancourt, Peter, Patel, Dipak R., Nirula, Ajay, Kallewaard, Nicole L., Higgs, Richard E., Benschop, Robert J.
Publicado 2021